✅ Model Answer:
• Diagnosis: Usher syndrome (most common deaf-blindness) — bilateral SNHL, retinitis pigmentosa (night blindness, progressive vision loss), vestibular dysfunction, abnormal ERG. Family history suggests autosomal recessive inheritance. Type 2A (USH2A) is most common.
• Any other test: Genetic testing (USH2A, MYO7A, CDH23, etc.), visual field testing (Goldmann perimetry), low-vision evaluation, vestibular assessment (caloric testing, posturography), full ophthalmologic exam.Retinitis pigmentosa (RP), ERG shows Reduced (retinal dysfunction)
• What to do next: Hearing aids/cochlear implant evaluation. Low-vision services (orientation and mobility training, visual aids). Family support, Deaf-Blind services. Educational planning (IEP/504 plan).
• Follow-up plan: Joint audiology-ophthalmology care. Monitor vision and hearing progression. Educational support (Braille, tactile sign, assistive technology). Genetic counseling for family. Psychological support for adolescent.

✅ Model Answer:
• Usher syndrome is the most common cause of deaf-blindness, characterized by sensorineural hearing loss and retinitis pigmentosa (progressive vision loss).
• Three major subtypes:
- Type 1 (USH1): Severe-profound congenital SNHL, absent vestibular function, early-onset retinitis pigmentosa (RP) (by adolescence). Genes: MYO7A, CDH23, PCDH15, USH1C, USH1G.
- Type 2 (USH2): Moderate-severe SNHL (congenital), normal vestibular function, later-onset RP (teens-20s). Most common (40-60%). Genes: USH2A, GPR98, DFNB31.
- Type 3 (USH3): Progressive post-lingual SNHL, variable vestibular function, later-onset RP. Gene: USH3A (CLRN1).
• Inheritance: Autosomal recessive.

✅ Model Answer:
• Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies affecting photoreceptor cells (rods and cones).
• Pathology: Progressive degeneration of rods (night blindness) → then cones (loss of color vision, central vision).
• Symptoms (progression):
- Early: Night blindness (nyctalopia) — difficulty seeing in dim light
- Mid: Peripheral vision loss ("tunnel vision")
- Late: Central vision loss → legal blindness
• Fundoscopy findings:
- Bone spicule pigmentation (peripheral retina)
- Optic disc pallor (waxy pallor)
- Arteriolar attenuation
• ERG (Electroretinogram): Reduced or extinguished responses (confirms RP).
• Prognosis: Progressive; most become legally blind by adulthood.

✅ Model Answer:
• Vestibular testing: Evaluates balance and inner ear function.
• In Usher syndrome:
- Type 1 (USH1): Vestibular dysfunction is always present — children walk late, have balance issues.
- Type 2 (USH2): Vestibular function is usually normal — no balance problems.
- Type 3 (USH3): Variable — may have vestibular dysfunction.
• Testing methods:
- Caloric testing: Evaluates horizontal semicircular canal function
- Posturography: Assesses balance control
- Vestibular evoked myogenic potentials (VEMPs): Tests otolith organs
• Clinical significance: Helps differentiate Usher subtypes and guides rehabilitation (physical therapy, balance training).

✅ Model Answer:
• Inheritance: Autosomal recessive (both parents are carriers).
• Genes: At least 12 genes identified, encoding proteins essential for cochlear and retinal function:
- USH2A: Most common gene (40-60% of Usher syndrome) — encodes usherin, a protein in the inner ear and retina
- MYO7A: Responsible for USH1B (most common USH1)
- CDH23: USH1D
- PCDH15: USH1F
- USH1C: USH1C
- CLRN1: USH3A
• Protein function: Involved in hair cell stereocilia (inner ear) and photoreceptor development (retina).
• Genetic testing: Panel testing or whole exome sequencing for diagnosis and subtype determination.

✅ Model Answer:
• Audiological management:
- Hearing aids: For mild-moderate SNHL (helpful for speech perception)
- Cochlear implants: For severe-profound SNHL (often beneficial in Usher, especially USH2)
- FM systems: For classroom use (improves signal-to-noise ratio)
- Sign language: Essential communication tool (ASL, tactile sign if vision loss)
- Speech therapy: For speech development
• Ophthalmological management:
- Low-vision aids: Magnifiers, telescopes, electronic aids
- Orientation and mobility (O&M) training: White cane, guide dog training
- Visual field monitoring: Perimetry to track progression
- ERG: To monitor retinal function
- Vitamin A supplementation: May slow progression (consult ophthalmologist)
- Future therapies: Gene therapy, retinal implants (clinical trials)

✅ Model Answer:
• Complications:
- Deaf-blindness: Dual sensory loss (hearing and vision) → significant impact on communication, mobility, and daily living
- Isolation: Difficulty socializing, participating in activities
- Educational challenges: Need for specialized teaching (Braille, tactile sign, assistive technology)
- Vestibular dysfunction: Balance issues (especially USH1)
- Visual impairment: Progressive vision loss → legal blindness by adulthood
• Psychosocial issues:
- Adolescence: Body image issues, peer relationships, sexuality (especially with vision loss)
- Depression/anxiety: Common due to dual sensory loss and isolation
- Independence: Need for orientation and mobility training, independent living skills
- Family impact: Stress on parents, siblings (caregiver burden)
- Career planning: Need for vocational rehabilitation
- Support groups: Important for coping and peer support

✅ Model Answer:
• Prognosis:
- Hearing: Stable in USH1 (profound), progressive in USH2 (may worsen), variable in USH3
- Vision: Progressive — night blindness in childhood, peripheral vision loss in teens/20s, central vision loss in 30s-40s (most become legally blind by adulthood)
- Vestibular: USH1 has no vestibular function; USH2 is normal; USH3 is variable
- Life expectancy: Normal
• Long-term management:
- Multidisciplinary team: Audiology, ophthalmology, low-vision, psychology, education
- Communication: ASL, tactile sign, braille, assistive technology
- Independent living: O&M training, daily living skills
- Vocational: Career guidance and vocational rehabilitation
- Genetic counseling: For family planning (25% recurrence risk for siblings)
- Support: Deaf-Blind services, support groups, mental health counseling
- Future: Gene therapy and retinal implants in clinical trials